Díliz PHS, Rossano GA

Idioma: Español
Referencias bibliográficas: 10
Paginas: 8-11
Archivo PDF: 57.54 Kb.

FRAGMENTO

Introducción

El trasplante hepático considerado en un tiempo como una modalidad experimental, ya desde la década de los ochenta del siglo pasado se consolidó como un procedimiento terapéutico utilizado mundialmente, con resultados satisfactorios; no sólo en sobrevida adecuada del injerto y del paciente sino como una medida que permite a los enfermos recuperar su expectativa de vida. La demanda por trasplante hepático a nivel mundial no sólo ha incrementado el número de procedimientos, sino que además ha experimentado una evolución significativa en técnicas quirúrgicas, indicaciones, tipo de donadores, de medicamentos inmunosupresores, cuidados postoperatorios y comprensión de los mecanismos inmunobiológicos involucrados en la “tolerancia” o rechazo del injerto.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Birth cohort effect on HCC prevalence among patients awaiting liver transplantation in the U.S. K. Bambha, S. Biggins, J. Dodge et al. U of Colorado Denver, UCSF.

2. Transplantation for hepatocellular carcinoma in younger patients has an equivocal survival advantage as compared to resection. JA Graham, MB Slidel, JK Melancon, et al. Children´s National Medical Center, Wahington, D. C.

3. Outcome of liver trasplantation for hepatocellular carcinoma according to different transplant criteria: A meta-analysis. Giacomo Germani, Matteo Garcovich, Kurinchi Gurusamy, Christian Toso, Patricia Burra, The Royal Free Saheila Sherlock Liver Centre and University Department of Surgery, London, United Kingdom; Hepato-Pancreato-Biliary and Liver Trasnplant Unit, University Department of Surgery, Royal Free Campus, UCL Medical Schoool, London, United Kingdom; Services de Chirurgie Viscerale et Transplantation Hopitaux Universitaires de Genéve, Switzerland, Gastroenterology, Department of Surgical and Gastroenterological Sciences, Padua, Italy.

4. Down-Staged HCC patients to Fit UCSF criteria showed excellent survivals: Further evidence in favor of biological tumor behavior in a single center. Allan M. Concejero, Chao-Long Chen, Yu-Fan Chen et al. Liver Transplant Program, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.

5. T-tube or not T-tube in deceased donor liver transplantation. Preliminary Results of a prospective randomized trial. Rafael López-Andujar, Eva Montalvá, Andrés Frange, Marina Berenguer, José Mir, et al. Hepatobiliary pancreatic Surgery and Transplantation Unit, La Fe University Hospital, Valencia, España.

6. Outcome of live donor liver transplantation in adults: Left vs Right Lobe. RF Saidi, Y Li, S. A. Sha, et al. Department of Surgery, University of Massachusetts Medical School.

7. Donor morbidity in living donor liver trasplantation: A single-center analysis of 827 cases. Milljae Shin, Sang Hun Song, Jong Man Kim, et al. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

8. Succesful liver transplantation using donation after cardiac death donors. B. Taner, I G Bulatao, D L Willingham, et al. Department of Transplantation, Mayo Clinic Florida, Jacksonville, Florida.

9. Six years of liver transplantation using grafts from controlled donors after cardiac death: A matched group comparison. Laura Taricotti, Chiara Rocha, Bridget Gunson et al. Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom.

10. Long-term complications after liver transplantation: results at 10 years after transplantation. M Berenguer, A. Rubin, J Mir, et al. Hospital la Fe, Valencia, España.